Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 250 of 722 results for pain management

  1. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

  2. Baricitinib for treating moderate to severe atopic dermatitis (TA681)

    Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.

  3. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG688)

    Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves surgically removing visible cancer and bathing the abdominal cavity with heated chemotherapy fluid to reach any remaining cancer cells.

  4. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

  5. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

  6. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  7. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (IPG685)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

  8. Accuro for guiding epidural or spinal anaesthesia (MIB245)

    NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .

  9. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    Question What is the clinical and cost effectiveness of opioids for the management of acute sciatica? Any explanatory notes(if...

  10. Suspected neurological conditions: recognition and referral (QS198)

    This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.

  11. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  12. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.

  13. Peripheral arterial disease: diagnosis and management (CG147)

    This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.

  14. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  15. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  16. Medicines Optimisation for Neuropathic Pain

    team sought to improve quality and efficiency of prescribing for neuropathic pain, whilst reducing variation in prescribing behaviour...

  17. Best evidence for a better back (BE FABB) - A triage, assessment and education service for patients with low back pain with or without sciatica

    Following the NICE Guidelines for Low back pain and sciatica in over 16s (NG59) we reviewed our pathway to ensure compliance

  18. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  19. Acute coronary syndromes in adults (QS68)

    This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.

  20. Magseed for locating impalpable breast cancer lesions (MIB236)

    NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .

  21. Human and animal bites: antimicrobial prescribing (NG184)

    This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.

  22. NICE, SIGN and RCGP set out further details about the UK guideline on management of the long-term effects of COVID-19

    NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP) have today (30 October 2020) given more details about the forthcoming guideline on post-COVID syndrome.

  23. Balloon cryoablation for Barrett's oesophagus (IPG682)

    Evidence-based recommendations on balloon cryoablation for Barrett’s oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  24. Balloon cryoablation for squamous dysplasia of the oesophagus (IPG683)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  25. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The World...

  26. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

  27. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) Why this is important Combination therapy is commonly prescribed for neuropathic...

  28. What is the most clinically and cost-effective timing and dose of a single administration of gabapentin to relieve pain in people undergoing surgery whose pain is expected to be moderate to severe?

    dose of a single administration of gabapentin to relieve pain in people undergoing surgery whose pain is expected to be...

  29. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    What is the clinical and cost effectiveness of antidepressants for the management of sciatica? Any explanatory notes(if applicable) Why...

  30. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    Question What is the clinical and cost effectiveness of opioids for the management of acute sciatica? Any explanatory notes(if...

  31. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    neuropathic pain? Any explanatory notes(if applicable) There has been some suggestion that some pharmacological agents for neuropathic...

  32. Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    symptoms that present in healthcare settings, or whether different neuropathic pain conditions with different aetiologies, respond...

  33. What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings...

  34. How should the symptomatic treatment of neuropathic pain relate to its cause?

    CG173/7 Question How should the symptomatic treatment of neuropathic pain relate to its cause? Any explanatory notes(if applicable)

  35. What is the clinical and cost effectiveness of alternative treatments as firstline treatment for trigeminal neuralgia compared with other better-tolerated pharmacological treatments?

    guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings...

  36. What is the clinical and cost effectiveness of lidocaine patches for localised peripheral pain?

    peripheral pain? Any explanatory notes(if applicable) Source guidance details Comes from guidance Neuropathic pain in...

  37. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain are...

  38. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

  39. Heavy menstrual bleeding (QS47)

    This quality standard covers assessing and managing heavy menstrual bleeding (menorrhagia), including suspected or confirmed fibroids and adenomyosis. It describes high-quality care in priority areas for improvement.

  40. World Evidence-Based Healthcare Day: Using evidence to inform our recommendations

    Dr Martin Allaby discusses World Evidence-Based Healthcare Day and how NICE uses evidence to inform our recommendations.

  41. Rheumatoid arthritis in adults: management (NG100)

    This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.

  42. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  43. Insect bites and stings: antimicrobial prescribing (NG182)

    This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.

  44. Adoption of high-sensitivity cardiac troponin for early rule out of Acute Myocardial Infarction (AMI) at the Royal Wolverhampton National Health Service (NHS) Trust

    which is in line with recommendations in section 1.2.5 of the NICE chest pain of recent onset guidance (CG95), focussed on...

  45. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  46. Surgical site infections: prevention and treatment (NG125)

    This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin. It focuses on methods used before, during and after surgery to minimise the risk of infection.

  47. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)

    Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.

  48. Commonly used treatments for chronic pain can do more harm than good and should not be used, says NICE in draft guidance

    A number of commonly used drug treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE has said in its draft clinical guideline published today (3 August 2020) on the assessment and management of chronic pain in over 16s.

  49. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  50. Spinal cord stimulator implantation: Improving theatre efficiency

    availability of beds and workforce challenges” (NHS Improvement 2019). NHS Pain Departments, along with other specialties, struggle for...